Açılan, Ceyda2022-03-212022-03-212010-10Ulukaya, E. vd. (2010). "sFas levels increase in response to cisplatin-based chemotherapy in lung cancer patients". Cell Biochemistry and Function, 28(7), 565-570.0263-64841099-0844https://doi.org/10.1002/cbf.1689https://onlinelibrary.wiley.com/doi/full/10.1002/cbf.1689http://hdl.handle.net/11452/25212The Fas/Fas Ligand (FasL) system and survivin have counteracting roles in cell survival. Therefore, we explored the role of circulating soluble Fas (sFas) and the tissue levels of Fas and survivin with regard to response to chemotherapy in lung cancer patients. Serum samples from 52 lung cancer patients and 54 control subjects (19 benign lung disease and 35 healthy control subjects) were collected prior to and 24 and 48 h after chemotherapy. sFas was statistically significantly higher in the cancer group than that in the control groups (p < 0.001). Baseline (before chemotherapy) sFas values showed a statistically significant inverse correlation with overall survival (r = -0.599, p < 0.001). There was a significant increase in serum sFas levels 24 h after treatment (p < 0.05). Contrarily, tissue levels of Fas and survivin were not changed following the chemotherapy (p > 0,05). In conclusion, increased sFas may be an indicator of poor outcome in lung cancer patients. However, cisplatin-based chemotherapy may not be effective via neither the Fas/FasL system nor survivin pathway. Indeed, larger sample size is required for further evaluation.eninfo:eu-repo/semantics/closedAccessApoptosisLung cancersFasFasSurvivinChemotherapySoluble fas levelPrognostic-significancePoor-prognosisLigand-expressionBreast-cancerSurvivin geneTumor-cellsSerumCD95Biochemistry & molecular biologyCell biologyAgedAntigens, CD95Antineoplastic agentsCisplatinFas ligand proteinFemaleHumansImmunohistochemistryLung neoplasmsMaleMicrotubule-associated proteinsMiddle agedPrognosisSurvival analysisTumor markers, biologicalArticle0002836152000052-s2.0-7865049159056557028720941746Biochemistry & molecular biologyCell biologyFas Ligand; Anti-Fas Monoclonal Antibody; Death Domain ReceptorsCisplatinEtoposideFas antigenFas ligandGemcitabineNavelbineSurvivinApoptosisArticleCancer chemotherapyCell survivalControlled studyFemaleHumanHuman tissueLung cancerMajor clinical studyMaleOverall survivalPriority journalProtein expressionProtein function